By the end of the RheumReview program, participants will be able to: apply new approaches to assessment and diagnosis for common rheumatic diseases in clinical practice, optimize novel therapies and therapeutic strategies for patients with common rheumatic diseases in clinical practice, gain awareness of the pipeline for future developments in the management of common rheumatic diseases.

Renal Disease in SLE:  Where Are We Now, Where Are We Going?
David Isenberg

In this session, we will consider renal lupus in the context of SLE as a whole but focus on the particular challenges it brings and how a better understanding of its causes and consequences is leading to more promising therapeutic prospects.

At the end of this session, participants will be able to:

1. Identify renal lupus in the context of the disease as a whole
2. Recognize the nature, causes, and consequences of renal failure

CanMEDS roles

1. Medical Expert
2. Leader
3. Scholar

ACR CHEST Guidelines for ILD in the SARDS
Sindhu Johnson

In this session, we will discuss the ACR CHEST guidelines for the screening, monitoring, and treatment of ILD in systemic autoimmune rheumatic diseases.

At the end of this session, participants will be able to:

1. Use appropriate screening & monitoring tests for ILD in the SARDs
2. Describe options for first-line treatment of ILD and progression of ILD despite first therapy
3. Apply treatment guidelines to cases

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Professional

How Should a Rheumatologist Manage a Patient with Pre-existing Rheumatic Disease Who Needs an Immune-checkpoint Inhibitor?
Carrie Ye

We will explore the evidence around the efficacy and safety of immune checkpoint inhibitors in patients with pre-existing rheumatic diseases. We will also discuss the impact of baseline immunosuppression on tumour outcomes and immune-related toxicity risk. Finally, we will examine potential long-term side effects of immune checkpoint inhibitors of which your rheumatology patients may be at increased risk.

At the end of this session, participants will be able to:

1. Describe the safety and efficacy of immune checkpoint inhibitors in patients with pre-existing rheumatic diseases
2. Assess the risks and benefits of baseline immunosuppression on tumour outcomes and toxicity rates
3. Understand the potential long-term side effects of immune checkpoint inhibitors

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Scholar

Inflammatory Arthritis and the Liver
Geneviève Huard

This session will review the liver diseases associated with inflammatory arthritis and review the impact of medication used to treat inflammatory arthritis on the liver.

At the end of this session, participants will be able to:

1. Recognize the different liver diseases associated with inflammatory arthritis
2. Evaluate the liver disease severity
3. Identify when to refer to a liver specialist

CanMEDS roles

1. Medical Expert
2. Professional

Serum Protein Electrophoresis Abnormalities:  What a Rheumatologist Needs to Know
Luke Chen

This session will provide an overview of the serum protein electrophoresis in Rheumatology patients, focusing on monoclonal gammopathies of clinical significance (e.g. Schnitzler syndrome) and the approach to polyclonal hypergammaglobulinemia.

At the end of this session, participants will be able to:

1. Interpret a serum protein electrophoresis (SPEP)
2. Understand a differential diagnosis for polyclonal hypergammaglobulinemia (PHGG)
3. Recognize important rheumatological monoclonal gammopathies of clinical significance (MCGS)

CanMEDS roles

1. Medical Expert
2. Scholar

An Update on ANCA Vasculitis
Daniel Ennis

In this session, we will review the new landmark trials in ANCA vasculitis with a focus on translation to clinical practice.

At the end of this session, participants will be able to:

1. Explain the appropriate applications of the PEXIVAS trial
2. Describe how to use Avacopan as a steroid replacement therapy
3. Identify new approaches to the management of EGPA

CanMEDS roles

1. Medical Expert
2. Collaborator
3. Health AdvocateScholar
4. Professional